Of note, polymorphisms in PNPLA3 and TM6SF might be “master regulators” of metabolic syndrome outcomes, which potentially determine the full range of NAFLD manifestations from hepatic fat accumulation to liver cancer [15]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.